- Home
- AII vs AVIR Comparison
AII vs AVIR Comparison
Compare AII & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AII
- AVIR
- Stock Information
- Founded
- AII 294
- AVIR 2012
- Country
- AII United States
- AVIR United States
- Employees
- AII N/A
- AVIR N/A
- Industry
- AII Property-Casualty Insurers
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AII Finance
- AVIR Health Care
- Exchange
- AII Nasdaq
- AVIR Nasdaq
- Market Cap
- AII 330.9M
- AVIR 273.7M
- IPO Year
- AII 2025
- AVIR 2020
- Fundamental
- Price
- AII N/A
- AVIR $2.63
- Analyst Decision
- AII
- AVIR Hold
- Analyst Count
- AII 0
- AVIR 1
- Target Price
- AII N/A
- AVIR $6.00
- AVG Volume (30 Days)
- AII 1.2M
- AVIR 525.1K
- Earning Date
- AII 01-01-0001
- AVIR 05-12-2025
- Dividend Yield
- AII N/A
- AVIR N/A
- EPS Growth
- AII N/A
- AVIR N/A
- EPS
- AII 309.45
- AVIR N/A
- Revenue
- AII $204,354,000.00
- AVIR N/A
- Revenue This Year
- AII N/A
- AVIR N/A
- Revenue Next Year
- AII N/A
- AVIR N/A
- P/E Ratio
- AII $0.06
- AVIR N/A
- Revenue Growth
- AII 1.73
- AVIR N/A
- 52 Week Low
- AII $0.59
- AVIR $2.60
- 52 Week High
- AII $2.69
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- AII N/A
- AVIR 39.68
- Support Level
- AII N/A
- AVIR $2.66
- Resistance Level
- AII N/A
- AVIR $3.01
- Average True Range (ATR)
- AII 0.00
- AVIR 0.15
- MACD
- AII 0.00
- AVIR -0.02
- Stochastic Oscillator
- AII 0.00
- AVIR 2.17
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).